ASH 2022: Talquetamab generates high response rate in patients with hard-to-treat multiple myeloma
In an early-phase trial, nearly three-quarters of patients who received talquetamab, a first-in-class experimental immunotherapy…
Browsing: ASH
ASH 2021: Immune-boosting antibody treatment isatuximab meets primary endpoint for multiple myeloma
Patients receiving the anti-CD38 monoclonal antibody isatuximab in addition to the standard three- component induction…
ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening
The first results from the largest screening study yet conducted in the United States of…